At the 92nd Annual Congress of the European Atherosclerosis Society (26-29 May 2024, Lyon, France, and online), Lp(a) presentations included recent data which demonstrated a causal link between Lp(a) and chronic kidney disease and underlined the importance of elevated Lp(a) in contributing to the risk of heterozygous familial hypercholesterolaemia. These topical presentations also encouraged the inclusion of Lp(a) measurement in lipid profiling, and supported novel approaches to targeting LPA gene expression for future Lp(a) lowering therapies.
Read the reports from EAS 2024:
